MetaCap

Niagen Bioscience Inc. (NAGE)

NASDAQ: NAGEHealth Care Medicinal Chemicals and Botanical Products USD

1.84-0.03 (-1.60%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NAGE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$145.72M
52-week range
1.79 – 7.11
Day range
1.79 – 1.86
Volume / Avg
1.39M / 522.66K
Beta
—

52-week range

$1.79$7.11

NAGE stock today

On Nov 20, NAGE ended the session at $1.84, shedding $0.03 (1.60%), versus the S&P 500's 3.70% decline. Volume was 2.7x the average at 1.39M shares, a sign of unusually heavy trading. Shares are 74.1% below their 52-week high of $7.11, set on Nov 25, 2025 and 2.8% above the 52-week low of $1.79, near the bottom of the past year's range.

NAGE is down 71.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 73.3%. Niagen Bioscience trades at 15.3x its trailing twelve-month earnings per share of $0.12.

Summary generated from market data by MetaCap's automated system. Methodology

About Niagen Bioscience

Company profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.

Industry
Medicinal Chemicals and Botanical Products
CEO
Mr. Robert N. Fried
Headquarters
Los Angeles, CA
Employees
117

Financial highlights

Full financials

In fiscal 2025, Niagen Bioscience generated $129.4 million in revenue, up 29.9% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $17.4 million (+103.3% year over year), for a net margin of 13.4% versus a median of -23.0% in the prior 5 years. Gross margin was 64.3% (up from 61.8%) and operating margin 12.6%.

Niagen Bioscience annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$129.42M$99.60M$83.57M$72.05M$67.45M
Growth+29.95%+19.18%+15.99%+6.82%+13.82%
Net income$17.38M$8.55M$-4.94M$-16.54M$-27.13M
EPS (diluted)$0.20$0.11$-0.07$-0.24$-0.40

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$10.67+479.89%

  • Strong buy 0
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $22.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.05 vs $-0.01
Surprise
+600.00%

NAGE news

All NAGE news

Niagen Bioscience peers

Health Care sector
NAGE peer companies
CompanyPrice% ChgMarket capCompare
GLASGlass House Brands Inc. Subordinate Voting Shares1.18-2.48%$118.11Mvs NAGE
CGCCanopy Growth Corporation0.427-9.97%$191.99Mvs NAGE
MDWDMediWound Ltd.13.59+0.37%$195.56Mvs NAGE
ISPRIspire Technology Inc.1.23-3.15%$71.05Mvs NAGE
FTLFFitLife Brands Inc.6.20-7.46%$58.22Mvs NAGE
USNAUSANA Health Sciences Inc.12.94-1.67%$239.24Mvs NAGE
BTMDBiote Corp. Class A0.8147-3.56%$26.28Mvs NAGE
ACBAurora Cannabis Inc.4.16-2.35%$273.50Mvs NAGE

Indexes, lists and sector

Niagen Bioscience stock FAQ

What is Niagen Bioscience's stock price today?

NAGE last traded at $1.84 as of Nov 20, 4:00 PM EST, down 1.60% on the day. Prices are delayed at least 15 minutes.

Does Niagen Bioscience pay a dividend?

No. Niagen Bioscience does not currently pay a regular cash dividend.

What is NAGE's P/E ratio?

NAGE trades at a trailing P/E ratio of 15.33.

Who is Niagen Bioscience's CEO?

Mr. Robert N. Fried is the chief executive officer of Niagen Bioscience Inc., which has about 117 employees.

Has NAGE ever split its stock?

Yes. The most recent NAGE stock split was a 1-for-3 split on Apr 13, 2016.

What is the NAGE 52-week high?

The 52-week high for NAGE is $7.11 and the 52-week low is $1.79. The stock is currently 74.1% below its high.

Compare NAGE